firstwordpharmaJuly 23, 2021
Icosavax plans to raise $150 million in its initial public offering by offering 10 million shares at a price range of $14 to $16, as reported by NASDAQ.
The company is developing its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life threatening respiratory diseases.
Icosavax’s lead program is IVX-A12, a bivalent candidate targeting both respiratory syncytial virus and human metapneumovirus.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: